Aslan Pharmaceuticals LT-ADRASLN
13F holders, Q3 2024 (September 30)1holders
$0.59avg. 13F price*
At the end of Q3 2024, 1 institutions reported holding Aslan Pharmaceuticals LT-ADR (ASLN) in their 13F filings. The largest holder was Rhumbline Advisers ($95).
- Company
- Aslan Pharmaceuticals LT-ADR
- CUSIP
- 04522R309
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $95 |
| Exits | 0 | $0 |
Ownership 1 holders
| Rhumbline Advisers | 0.00% | New | 160 | $95 |
"% of holder's portfolio" is ASLN's weight in each manager's 13F, not the share of Aslan Pharmaceuticals LT-ADR the manager owns.